Antitumor activity of gambogic acid on NCI-H1993 xenografts via MET signaling pathway downregulation Corrigendum in /10.3892/ol.2021.12477

Li,Donglei; Yang,Huiwei; Li,Runpu; Wang,Yanli; Wang,Weijun; Li,Dongjie; Ma,Shaolin; Zhang,Xuyu

doi:10.3892/ol.2015.3719

Antitumor activity of gambogic acid on NCI-H1993 xenografts via MET signaling pathway downregulation

Corrigendum in: /10.3892/ol.2021.12477

Authors:
- Donglei Li
- Huiwei Yang
- Runpu Li
- Yanli Wang
- Weijun Wang
- Dongjie Li
- Shaolin Ma
- Xuyu Zhang
View Affiliations

Affiliations: Oncology Department, Baoding Second Central Hospital of Oncology, Zhuozhou, Hebei 072750, P.R. China
Published online on: September 17, 2015 https://doi.org/10.3892/ol.2015.3719
Pages: 2802-2806
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the anti-tumor mechanisms of gambogic acid (GA) on NCI-H1993 xenografts in vivo. Non-small cell lung carcinoma NCI-H1993 cells, which harbor a MET gene amplification, were subcutaneously injected into athymic nude mice. The mice were randomly assigned to treatment with 10, 20 or 30 mg/kg GA for 3 weeks. At the end of the efficacy study, all the mice were sacrificed and the tumor tissues were subjected to western blot analysis and immunohistochemical (IHC) staining. GA inhibited NCI‑H1993 xenograft tumor growth in a dose‑dependent manner. Western blot analysis demonstrated that expression of phosphorylated (p)‑MET and its downstream signaling molecules p‑AKT and p‑ERK1/2 were significantly inhibited by GA. IHC analysis of Ki‑67 expression demonstrated that GA treatment resulted in dose‑dependent inhibition of tumor cell proliferation. GA exerted antitumor effects on NCI‑H1993 xenografts in vivo by direct regulation of the MET signaling pathway. Theses antitumor effects were primarily a result of its anti-proliferation function.

View Figures

View References

1	Maestrini E, Tamagnone L, Longati P, et al: A family of transmembrane proteins with homology to the MET-hepatocyte growth factor receptor. Proc Natl Acad Sci USA. 93:674–678. 1996. View Article : Google Scholar : PubMed/NCBI
2	Sattler M and Salgia R: c-Met and hepatocyte growth factor: Potential as novel targets in cancer therapy. Curr Oncol Rep. 9:102–108. 2007. View Article : Google Scholar : PubMed/NCBI
3	Guo Q, Qi Q, You Q, Gu H, Zhao L and Wu Z: Toxicological studies of gambogic acid and its potential targets in experimental animals. Basic Clin Pharmacol Toxicol. 99:178–184. 2006. View Article : Google Scholar : PubMed/NCBI
4	Wu ZQ, Guo QL, You QD, et al: Gambogic acid inhibits proliferation of human lung carcinoma SPC-A1 cells in vivo and in vitro and represses telomerase activity and telomerase reverse transcriptase mRNA expression in the cells. Biol Pharm Bull. 27:1769–1774. 2004. View Article : Google Scholar : PubMed/NCBI
5	Guo QL, Lin SS, You QD, et al: Inhibition of human telomerase reverse transcriptase gene expression by gambogic acid in human hepatoma SMMC-7721 cells. Life Sci. 78:1238–1245. 2006. View Article : Google Scholar : PubMed/NCBI
6	Wang X, Lu N, Yang Q, et al: Studies on chemical modification and biology of a natural product, gambogic acid (III): Determination of the essential pharmacophore for biological activity. Eur J Med Chem. 46:1280–1290. 2011. View Article : Google Scholar : PubMed/NCBI
7	Wang J, Zhao L, Hu Y, et al: Studies on chemical structure modification and biology of a natural product, Gambogic acid (I): Synthesis and biological evaluation of oxidized analogues of gambogic acid. Eur J Med Chem. 44:2611–2620. 2009. View Article : Google Scholar : PubMed/NCBI
8	Pandey MK, Sung B, Ahn KS, et al: Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF induced apoptosis through modulation of the nuclear factor-kappaB signaling pathway. Blood. 110:3517–3525. 2007. View Article : Google Scholar : PubMed/NCBI
9	Yi T, Yi Z, Cho SG, et al: Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Res. 68:1843–1850. 2008. View Article : Google Scholar : PubMed/NCBI
10	Zhu X, Zhang H, Lin Y, et al: Mechanisms of gambogic acid-induced apoptosis in non-small cell lung cancer cells in relation to transferrin receptors. J Chemother. 21:666–672. 2009. View Article : Google Scholar : PubMed/NCBI
11	Wang LH, Li Y, Yang SN, et al: Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signaling. Br J Cancer. 110:341–352. 2014. View Article : Google Scholar : PubMed/NCBI
12	Sunaga N, Shames DS, Girard L, et al: Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy. Mol Cancer Ther. 10:336–346. 2011. View Article : Google Scholar : PubMed/NCBI
13	Gu HY, Guo QL, You QD, et al: Gambogic acid inducing apoptosis in human hepatoma SMMC-7721 cells with p53 and Bax up-regulated. Chin J Nat Med. 3:169–171. 2005.
14	Liu W, Guo QL, You QD, et al: Anticancer effect and apoptosis induction of gambogic acid in human gastric cancer line BGC-823. World J Gastroenterol. 11:3655–3659. 2005. View Article : Google Scholar : PubMed/NCBI
15	Zhao L, Guo QL, You QD, et al: Gambogic acid induces apoptosis and regulates expressions of Bax and Bcl-2 protein in human gastric carcinoma MGC-803 cells. Biol Pharm Bull. 27:998–1003. 2004. View Article : Google Scholar : PubMed/NCBI
16	Zhou Z and Wang J: Phase I human tolerability trial of gambogic acid. Chin J New Drugs. 16:79–82. 2007.
17	Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
18	Maulik G, Kijima T, Ma PC, et al: Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res. 8:620–627. 2002.PubMed/NCBI
19	Zhao W, Zhou SF, Zhang ZP, et al: Gambogic acid inhibits the growth of osteosarcoma cells in vitro by inducing apoptosis and cell cycle arrest. Oncol Rep. 25:1289–1295. 2011.PubMed/NCBI
20	Yang Y, Yang L, You QD, et al: Differential apoptotic induction of gambogic acid, a novel anticancer natural product, on hepatoma cells and normal hepatocytes. Cancer Lett. 256:259–266. 2007. View Article : Google Scholar : PubMed/NCBI
21	He XY, Liu XJ, Chen X, et al: Gambogic acid induces EGFR degradation and Akt/mTORC1 inhibition through AMPK dependent-LRIG1 upregulation in cultured U87 glioma cells. Biochem Biophys Res Commun. 435:397–402. 2013. View Article : Google Scholar : PubMed/NCBI